7月31日，诚意药业（603811）(603811.SH)公告，公司旗下帕拉米韦注射液近日获得药监局核准签发的 《药品注册证书》，作为化药3类药品获批上市。据悉，该药物适用于治疗甲型或乙型流行性感冒。 研发支撑品类扩充，支撑长期业绩表现的同时，公司核心产品关节类药物自2024年以来也为公司贡献了 亮眼的业绩。据2025年中报业绩预告，上半年公司预计实现归母净利润1.07亿元至1.19亿元，同比增长 40%至55%，关节类药物销售的持续增长是主要原因之一。 此外，围绕海洋生物医药，诚意药业以"两强一大项目"建设为核心，千吨级超级鱼油EPA产能项目建设 也正稳步推进，未来有望成为继关节类药物外公司另一业绩核心支柱，在降脂类药物领域打开新的市场 空间。 此次药品获批，虽短期对诚意药业业绩表现无直接影响，但印证了公司在药品研发方面持续投入的成 果。公告也指出，公司高度重视药品研发，并严格控制药品研发、制造及销售环节的质量及安全。 值得一提的是，近1年以来，诚意药业在制剂领域已有多款产品获批上市，产品线得到持续扩充。2024 年9月，用于慢性肾衰并发症的左卡尼汀注射液获批上市；2025年1月，用于绝经后骨质疏松、慢性肾 ...

Core Viewpoint - Chengyi Pharmaceutical reported significant growth in revenue and net profit for 2024 and Q1 2025, highlighting its strategic focus on marine biomedicine and integrated drug production [1] Financial Performance - In 2024, the company's revenue reached 714 million yuan, a year-on-year increase of 6.36%, while the net profit attributable to shareholders was 201 million yuan, reflecting a substantial growth of 23.21% [1] - For Q1 2025, revenue was 186 million yuan, showing a year-on-year growth of 21.26%, and net profit was 45.79 million yuan, up 40.10% compared to the previous year [1] - The company plans to distribute a cash dividend of 2.5 yuan per 10 shares, totaling approximately 79.42 million yuan, alongside a share buyback of 67.26 million yuan, amounting to a total of 147 million yuan, which represents 73.09% of the net profit [1] Product and Market Development - Revenue from joint disease medications in 2024 was 502 million yuan, marking a year-on-year increase of 23.41%, with Q1 2025 revenue at 143 million yuan, a significant rise of 49.62% [1] - Chengyi Pharmaceutical is the first listed company in Zhejiang Province focusing on marine biomedicine, with its core product, glucosamine hydrochloride, sourced from chitin derived from crab and shrimp shells, establishing itself as a major supplier in China [1] - The company has six domestic health food products, with the new "Haicuiwei Fish Oil Soft Capsule" expected to complete registration and launch by December 2024 [1] Strategic Initiatives - Chengyi Pharmaceutical is actively developing a production capacity project for 1,000 tons of super fish oil EPA and is pushing for the application of new drugs such as EPA soft capsules [1] - During the reporting period, several products, including lidocaine injection and amikacin sulfate injection, passed consistency evaluations, while new products like calcitriol soft capsules and levocarnitine injection received approval [1] - The company aims to focus on four major industrial sectors and deepen its integrated strategy of "raw materials + formulations" [1]